XML 37 R21.htm IDEA: XBRL DOCUMENT v3.22.1
STOCK OPTIONS
12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
STOCK OPTIONS

NOTE 14 – STOCK OPTIONS

 

Our stockholders approved our 2014 Equity Incentive Plan in June 2014 (the “2014 Plan”), our 2015 Equity Incentive Plan in December 2015 (the “2015 Plan”), our 2016 Equity Incentive Plan in October 2016 (“2016 Plan”), our 2017 Equity Incentive Plan in December 2016 (“2017 Plan” and together with the 2014 Plan, 2015 Plan, 2016 Plan, the “Prior Plans”), our 2018 Equity Incentive Plan in June 2018 (the “2018 Plan”), and our 2021 Equity Incentive Plan in September 2021 (“2021 Plan” , and together with the Prior Plans, the “Plans”). The Prior Plans are identical, except for the number of shares reserved for issuance under each. As of December 31, 2021, the Company had granted an aggregate of 214,367 securities under the Plans since inception, with 167,300 shares available for future issuances. The Company made no grants under the plans during the years ended December 31, 2021 and 2020.

 

 

The Plans provide for the grant of incentive stock options to our employees and our subsidiaries’ employees, and for the grant of stock options, stock bonus awards, restricted stock awards, performance stock awards and other forms of stock compensation to our employees, including officers, consultants and directors. The Prior Plans also provide that the grant of performance stock awards may be paid out in cash as determined by the committee administering the Prior Plans.

 

Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option pricing model with a volatility figure derived from historical data. The Company accounts for the expected life of options based on the contractual life of the options.

 

There were no options issued during the years ended December 31, 2021 and 2020.

 

A summary of the stock option activity for the years ended December 31, 2021 and 2020 is as follows:

 

   Shares   Weighted-
Average
Exercise
Price
   Weighted-
Average
Remaining
Contractual
Term
   Aggregate
Intrinsic
Value
 
Outstanding at December 31, 2019   92,116   $148.11    7.49   $- 
Granted   -                
Exercised   -                
Forfeiture/Cancelled   -                
Outstanding at December 31, 2020   92,116   $148.11    6.49   $- 
Granted   -                
Exercised   -                
Forfeiture/Cancelled   -                
Outstanding at December 31, 2021   92,116   $148.11    5.49   $- 
Exercisable at December 31, 2021   92,116   $148.11    5.49   $- 

 

 

 

Exercise Price

  Number of
Options
   Remaining Life
In Years
  

Number of

Options
Exercisable

 
$ 30.00-75.00   44,368    6.26    44,368 
  75.01-150.00   6,479    5.26    6,479 
  150.01-225.00   6,079    4.68    6,079 
  225.01-300.00   33,133    4.70    33,133 
  300.01-600.00   2,110    4.60    2,110 
      92,116         92,116 

 

The aggregate intrinsic value of outstanding stock options was $0, based on options with an exercise price less than the Company’s stock price of $14.10 as of December 31, 2021, which would have been received by the option holders had those option holders exercised their options as of that date.

 

The fair value of all options that were vested as of the year ended December 31, 2021 and 2020 was $0 and $0, respectively. Unrecognized compensation expense of $0 as of December 31, 2021 will be expensed in future periods.